Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

(2021) James F Howard et al.   LANCET NEUROLOGY

Development of the Myasthenia Gravis (MG) Symptoms PRO: a case study of a patient-centred outcome measure in rare disease

(2021) Sophie Cleanthous et al.   Orphanet Journal of Rare Diseases

The Lived Experience of Myasthenia Gravis: A Patient-Led Analysis

(2021) Nancy Law et al.   Neurology and Therapy

MuSK-Associated Myasthenia Gravis: Clinical Features and Management

(2020) Carmelo Rodolico et al.   Frontiers in Neurology

Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis

(2019) James F. Howard et al.   NEUROLOGY

Myasthenia gravis

(2019) Nils Erik Gilhus et al.   Nature Reviews Disease Primers

Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis

(2018) Karen Hewett et al.   NEUROLOGY

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

(2017) James F Howard et al.   LANCET NEUROLOGY

Inpatient cost analysis for treatment of myasthenia gravis

(2017) Jacklyn O. Omorodion et al.   MUSCLE & NERVE

International consensus guidance for management of myasthenia gravis

(2016) Donald B. Sanders et al.   NEUROLOGY

Myasthenia gravis: subgroup classification and therapeutic strategies

(2015) Nils Erik Gilhus et al.   LANCET NEUROLOGY

The Role of MuSK in Synapse Formation and Neuromuscular Disease

(2013) S. J. Burden et al.   Cold Spring Harbor Perspectives in Biology

The economic cost of brain disorders in Europe

(2011) J. Olesen et al.   EUROPEAN JOURNAL OF NEUROLOGY

MG-ADL: Still a relevant outcome measure

(2011) Srikanth Muppidi et al.   MUSCLE & NERVE

The MG Composite: A valid and reliable outcome measure for myasthenia gravis

(2010) T. M. Burns et al.   NEUROLOGY

Review: Progress in the treatment of myasthenia gravis

(2008) Ralf Gold et al.   Therapeutic Advances in Neurological Disorders